The covid-19 intranasal vaccine iNCOVACC, which is currently accessible on the CoWIN portal, is priced at Rs 800 (excluding GST) for commercial markets and Rs 325 (excluding GST) for government supply, according to a statement released on Tuesday by Bharat Biotech International Limited.
The vaccine is scheduled to be administered in the fourth week of January 2023, according to a press release from the manufacturer. The first intranasal covid vaccination in the world to be approved for both a heterologous booster dose and the primary two-dose schedule is iNCOVACC.
The Central Drugs Standard Control Organization (CDSCO) authorised Bharat Biotech permission to employ heterologous booster doses of iNCOVACC earlier this month. “We have developed Covaxin and iNCOVACC, two covid vaccines from two different platforms, with two different delivery systems. The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunisation during public health emergencies and pandemics,” Krishna Ella, Executive Chairman of BBIL, said.
According to the press release, phase-III trials of iNCOVACC (as a two-dose regimen) were carried out for safety and immunogenicity in almost 3100 people across 14 trial sites in India, while heterologous booster dosage studies were carried out in 875 people for safety and immunogenicity.
In collaboration with Washington University in St. Louis, which created the recombinant adenoviral vectored construct and tested its efficiency in pre-clinical research, iNCOVACC was created.